



Amarin Corporation plc  
 Investor Relations Department  
 2 Pembroke House, Upper  
 Pembroke  
 Street 28-32  
 Dublin 2  
 Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

Last Trade:	3.13
Trade Time:	4:00 PM ET Mar 21, 2018
Change:	-0.07  (-2.188%)
Day Range	3.11 - 3.29
52-Week Range	2.85 - 4.60
Volume	4,173,005

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Mar 21, 2018*  
[Amarin Announces First Middle East Approval for Vascepa®](#)
- Mar 12, 2018*  
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein \(hsCRP\)](#)
- Mar 12, 2018*  
[Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs](#)
- Mar 5, 2018*  
[Amarin Announces Closing of Underwriter's Purchase of Additional Shares](#)
- Mar 1, 2018*  
[Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study](#)

**Financials** [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 27, 2018*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)